Cargando…

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma

Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography attenuation correction (PET-CT) in myeloma can detect and enumerate focal lesions by the quantitative characterization of metabolic activity. The aim of this study was to determine the prognostic significance of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Faith E., Rosenthal, Adam, Rasche, Leo, Petty, Nathan M., McDonald, James E., Ntambi, James A., Steward, Doug M., Panozzo, Susan B., van Rhee, Frits, Zangari, Maurizio, Schinke, Carolina D., Thanendrarajan, Sharmilan, Walker, Brian, Weinhold, Niels, Barlogie, Bart, Hoering, Antje, Morgan, Gareth J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058800/ https://www.ncbi.nlm.nih.gov/pubmed/29567784 http://dx.doi.org/10.3324/haematol.2017.177139

Ejemplares similares

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states
por: Rasche, Leo, et al.
Publicado: (2022)

Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
por: Rasche, Leo, et al.
Publicado: (2019)

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma
por: Al Hadidi, Samer, et al.
Publicado: (2023)

The Clinical Value of Molecular Subtyping Multiple Myeloma Using Gene Expression Profiling
por: Weinhold, N, et al.
Publicado: (2015)

Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns
por: Schinke, Carolina, et al.
Publicado: (2020)

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level
por: Schinke, Carolina, et al.
Publicado: (2022)

Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
por: Alqazaqi, Raghad, et al.
Publicado: (2022)

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome
por: Sawyer, Jeffrey R., et al.
Publicado: (2019)

Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
por: Mazahreh, Farah, et al.
Publicado: (2023)

3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns
por: Schinke, Carolina, et al.
Publicado: (2019)

Variability of definition of high‐risk multiple myeloma across phase III clinical trials
por: Abu Za'nouneh, Faris Jamal, et al.
Publicado: (2023)

EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
por: Ling, Wen, et al.
Publicado: (2023)

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53
por: Ashby, Cody, et al.
Publicado: (2019)

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma
por: Jethava, Y, et al.
Publicado: (2016)

The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma
por: Choudhury, Samrat Roy, et al.
Publicado: (2020)

Kinase domain activation through gene rearrangement in multiple myeloma
por: Morgan, Gareth J, et al.
Publicado: (2018)

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker
por: Chavan, S S, et al.
Publicado: (2017)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Gai, Dongzheng, et al.
Publicado: (2022)

Infection Risk Associated with Daratumumab
por: Johnsrud, Joyce J, et al.
Publicado: (2017)

Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2023)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing
por: Rasche, L., et al.
Publicado: (2017)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
por: Yarlagadda, Lakshmi, et al.
Publicado: (2021)

Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant
por: Thalambedu, Nishanth, et al.
Publicado: (2022)

Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
por: Larsen, Kristin, et al.
Publicado: (2022)

Enterococcus raffinosus infection with atypical hemolytic uremic syndrome in a multiple myeloma patient after autologous stem cell transplant
por: Mathur, Pankaj, et al.
Publicado: (2017)

Positron emission tomography/computerized tomography imaging of multiple focus of neurolymphomatosis
por: Peterson, James, et al.
Publicado: (2014)

Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
por: Baker, David, et al.
Publicado: (2021)

Positron emission tomography
Publicado: (1995)

Positron Emission Tomography
por: Piepmeier, Joseph M.
Publicado: (1986)

Positron emission tomography
por: Paans, A M J
Publicado: (2006)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Tumor Quantification in Clinical Positron Emission Tomography
por: Bai, Bing, et al.
Publicado: (2013)

Quantitative accuracy of positron emission tomography/magnetic resonance and positron emission tomography/computed tomography for cervical cancer
por: Oldan, Jorge Daniel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q92tcal64mr0mstole11mu90v2